Evidence map›Paper›PMID 24466075›Full record

ArticlePloS one2014

Adiponectin expression protects against angiotensin II-mediated inflammation and accelerated atherosclerosis.

Caroline M W van Stijn, Jason Kim, Grant D Barish, Uwe J F Tietge, Rajendra K Tangirala

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 67 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Caroline M W van StijnDivision of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America.
Jason KimDivision of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America.
Grant D BarishDivision of Endocrinology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America.
Uwe J F TietgeDepartment of Pediatrics, University of Groningen Medical Center, Groningen, The Netherlands.
Rajendra K TangiralaDivision of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America.
University of California, Los Angeles · USNorthwestern University · USUniversity Medical Center Groningen · NL

Funding

Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PETER J TONTONOZ · 2003 to 2026
$40.4M
Adiponectin Actions on the Monocyte to Reduce AtherosclerosisR01HL086566 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TANGIRALA, RAJENDRA K · 2009 to 2013
$1.9M
NHLBI NIH HHS HL086566NHLBI NIH HHS R01 HL086566NIDDK NIH HHS P30 DK063491NIDDK NIH HHS P30DK063491
6 · The paper itself

Abstract

Adiponectin (APN), an adipocytokine produced by adipose tissue, exerts pleiotropic actions regulating inflammation, metabolism and vascular homeostasis. APN levels are inversely correlated with obesity, type-2 diabetes, hypertension and cardiovascular disease. Although renin angiotensin system (RAS) activation in these interrelated metabolic syndrome components increases angiotensin II (AngII) levels leading to vascular damage, it is unknown whether APN under these conditions provides atheroprotection. We investigated whether increasing plasma APN provides atheroprotection in a hypertensive and accelerated atherosclerosis model. Using adenoviral gene transfer, sustained APN expression increased plasma levels of total and high-molecular weight APN, leading to a significant elevation of plasma HDL-cholesterol (HDL-C). Elevated APN levels were strongly atheroprotective, yet had no impact on blood pressure. Notably, gene expression analyses revealed that APN significantly inhibited the expression of pro-inflammatory and atherogenic genes while it increased the expression of the anti-inflammatory cytokine, IL-10 and the cholesterol efflux transporters, ABCA1 and ABCG1 in the artery wall. These findings suggest that increasing APN levels may be an effective therapeutic strategy to inhibit vascular inflammation and accelerated atherosclerosis associated with RAS activation in the metabolic syndrome.

Indexed as

Gene ExpressionAdiponectinAngiotensin IIAnimalsApolipoproteinsAtherosclerosisBlood PressureCholesterolDisease Models, AnimalHypertensionInflammationLiverMacrophagesMaleMiceMice, KnockoutAdiponectinAngiotensin IIApolipoproteinsCholesterolReceptors, AdiponectinReceptors, LDLReceptors, Scavenger

Identifiers

PMID24466075
PMCPMC3899253
OpenAlexW2015791938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.